Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NervGen Pharma Corp NGENF


Primary Symbol: V.NGEN

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. It has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The Company's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.


TSXV:NGEN - Post by User

Post by deepoil0808on Apr 09, 2024 11:38pm
278 Views
Post# 35980483

UGLY chart speaks VOLUMES

UGLY chart speaks VOLUMESI am thinking out loud.   

If the treatment really worked we would have seen a soaring stock price as results are evident by staff, by doctors, by family members etc.... It would be tough to control a leak. 

But stock price is plunging.....so it must mean something....

It might mean that trials maybe INCONCLUSIVE at this stage and more research needs to be done. 

The raising of cash would then make sense as the company wants money for more trials and, investors are willing to pay up because they hope that future trials will be more conclusive.

In any event, this is my personal opinion, just my 2 cents.

I am waiting for results.  Does not matter if I am wrong because any entry on the first day of good evidence is good as stock will then rally for years.

But if results are bad, then penny status it is and it might never recover. 

So weigh the risks.   

I want to see evidence first.

Good Luck

My personal opinion, 
<< Previous
Bullboard Posts
Next >>